AKBAR RIZVI
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology MCKINNEY, TX NPI 1225023948
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology TX NOVARTIS PHARMACEUTICALS CORPORATION All categories
General Payments — all program years on this page
$5,753.60
- Category: General Payments
- Program years: PY2018–2024
- Record count: 283
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $1,978.50 across 64 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,196.98 | 56 |
| Long term medical supply or device loan | $681.53 | 7 |
| Education | $99.99 | 1 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| NOVARTIS PHARMACEUTICALS CORPORATION | $743.83 | 11 |
| PFIZER INC. | $161.85 | 9 |
| Janssen Biotech, Inc. | $118.37 | 4 |
| Acerta Pharma LLC | $108.80 | 4 |
| SANOFI-AVENTIS U.S. LLC | $99.99 | 1 |
| Incyte Corporation | $76.56 | 3 |
| Daiichi Sankyo Inc. | $75.34 | 3 |
| Medtronic, Inc. | $58.18 | 3 |
| Gilead Sciences, Inc. | $51.48 | 3 |
| ARRAY BIOPHARMA INC | $44.73 | 2 |
| Astellas Pharma US Inc | $44.63 | 2 |
| Alnylam Pharmaceuticals Inc. | $44.55 | 2 |
| Sirtex Medical Inc | $36.44 | 1 |
| Janssen Pharmaceuticals, Inc | $30.59 | 2 |
| Inari Medical, Inc. | $28.22 | 1 |
| Kite Pharma, Inc. | $24.86 | 1 |
| Genmab U.S., Inc. | $23.32 | 1 |
| EMD Serono, Inc. | $23.09 | 1 |
| Kyowa Kirin, Inc. | $21.34 | 1 |
| ABBVIE INC. | $21.16 | 1 |
| SECURA BIO, INC. | $20.32 | 1 |
| E.R. Squibb & Sons, L.L.C. | $18.72 | 1 |
| Acrotech Biopharma Inc. | $18.70 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $18.69 | 1 |
| GlaxoSmithKline, LLC. | $17.86 | 1 |
| ADC Therapeutics America, Inc. | $15.86 | 1 |
| GENZYME CORPORATION | $15.54 | 1 |
| Celgene Corporation | $15.48 | 1 |
By program year
Records — PY2024 (64)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.